53 terminated. 53 Phase 2, 8 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 53 | Terminated 53 |
| Phase 1 | 8 | Terminated 8 |
| Phase 3 | 3 | Terminated 3 |
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Dupilumab, Placebo, IBI356 - Atopic Dermatitis | Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 18 | 2025-12-31 | 2026-10-27 |
| A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) Dupilumab, JNJ-95475939, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 256 | 2025-02-26 | 2026-07-31 |
| Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 79 | 2024-06-05 | 2026-06-16 |
| A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | GlaxoSmithKline | 161 | 2023-11-16 | 2026-06-03 |
| Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis SAR444656 (KT-474), Placebo - Atopic Dermatitis | Phase 2 | Terminated | Sanofi | 70 | 2023-11-09 | 2026-11-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
| A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis LY3454738, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Eli Lilly and Company | 234 | 2023-06-21 | 2025-12-02 |
| Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) Dermaprazole 1%, Dermaprazole 2% - Radiation Dermatitis, Breast Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 3 | 2023-04-24 | 2026-02-17 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis BMX-010, Placebo - Atopic Dermatitis | Phase 2 | Terminated | BioMimetix JV, LLC | 103 | 2023-01-08 | 2024-04-18 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis AK002, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Allakos Inc. | 131 | 2022-06-27 | 2024-10-15 |
| Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation Application of Tralokinumab - Atopic Dermatitis | Phase 2 / Phase 3 | Terminated | University of Zurich | 24 | 2022-06-15 | 2026-02-06 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis RPT193, Placebo - Atopic Dermatitis | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 229 | 2022-06-07 | 2026-03-23 |
| A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials EDP1815 - Atopic Dermatitis | Phase 2 | Terminated | Evelo Biosciences, Inc. | 287 | 2022-06-06 | 2023-09-07 |
| Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD Broncho-Vaxom, Placebo - Atopic Dermatitis | Phase 2 | Terminated | OM Pharma SA | 63 | 2021-12-20 | 2023-08-08 |
| Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel DBI-001, Aqueous gel - Atopic Dermatitis | Phase 2 | Terminated | DermBiont, Inc. | 10 | 2021-10-06 | 2023-11-08 |
| Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Placebo, AK120 - Atopic Dermatitis | Phase 2 | Terminated | Akesobio Australia Pty Ltd | 79 | 2021-09-30 | 2025-02-26 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Bermekimab, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | Janssen Research & Development, LLC | 6 | 2021-09-02 | 2023-05-24 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study FB-401 - Atopic Dermatitis | Phase 2 | Terminated | Forte Biosciences, Inc. | 36 | 2021-06-02 | 2021-10-28 |
Showing 20 of 53. Sign in to see all of them.
Dermatitis, Atopic (45) · Eczema (14) · Breast Neoplasms (4) · Immune System Diseases (4) · Pruritus (4) · Skin Diseases (4) · Lymphoma, Follicular (3) · Radiodermatitis (3) · Hand-Foot Syndrome (2) · Psoriasis (2) · Stevens-Johnson Syndrome (2) · Alopecia (1) · Dermatitis, Seborrheic (1) · Inflammation (1)
Skin and Connective Tissue Diseases (53) · Skin Diseases (49) · Hypersensitivity (47) · Skin Diseases, Eczematous (46) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (45) · Genetic Diseases, Inborn (45) · Hypersensitivity, Immediate (45) · Skin Diseases, Genetic (45) · Immune System Diseases (43) · Neoplasms (8) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (6) · Skin Manifestations (5) · Breast Diseases (4)
dupilumab (4) · GSK1070806 (2) · bermekimab (2) · itepekimab (2) · 8,11,14-Eicosatrienoic Acid (1) · AK002 (1) · BANG polymer gel (1) · Brimonidine Tartrate (1) · Broncho-Vaxom (1) · Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Lamotrigine (1) · Oils (1) · Petrolatum (1) · Therapeutics (1)
GlaxoSmithKline (3) · Janssen Research & Development, LLC (3) · Regeneron Pharmaceuticals (3) · DermBiont, Inc. (2) · Eli Lilly and Company (2) · Lakefront Biotherapeutics NV (2) · Novartis Pharmaceuticals (2) · Akesobio Australia Pty Ltd (1) · Allakos Inc. (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Amgen (1) · Arjil Pharmaceuticals LLC (1) · Asana BioSciences (1) · AstraZeneca (1) · Baylor College of Medicine (1)
United States (39) · Germany (18) · Poland (18) · Canada (17) · Japan (12) · Czechia (9) · Spain (9) · South Korea (7) · Hungary (6) · United Kingdom (6) · Argentina (5) · Australia (5) · France (5) · Taiwan (5) · Bulgaria (4)
Alex Zvulunov, Prof (1) · Avner Shemer, Prof (1) · Ben Ehst, PhD (1) · Benjamin Ungar, MD (1) · Chin Lee, MD, MPH (1) · Daisy Blanco, MD (1) · Dalia Gilat, Dr. (1) · Daniel A Hamstra, MD, PhD (1) · David Zammit, Ph.D. (1) · Douglas Maslin, MD (1)
2018 (5), 2023 (3), 2017 (1)